Find a Phase 1 clinical trial

The table below shows a list of the Experimental Cancer Medicine Team's currently recruiting phase I clinical trials. The arrow links will guide you to clinicaltrials.gov. This is an external public domain database showing clinical trials from around the world.

If you are a patient and you are interested in taking part in a clinical trial listed below, please talk to your oncologist or doctor about the trial you are interested in. We cannot accept nor respond to direct patient requests to participate on a clinical trial. If you are a patient you must be referred to us from your treating physician.

Oncologists working at external sites should contact centralregistration@christie.nhs.uk

If you are an Oncologist from within The Christie you are able to use this referral form to refer patients.

Target mechanism of investigative drug

Title of clinical trial

Hyperlink

C34003 (TAK-659 in Combination with Nivolumab)

A Phase 1b Study to Evaluate TAK-659 in Combination With Nivolumab in Patients With Advanced Solid Tumors

INCB001158 (Arginase inhibitor)

A Phase 1/2 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in Subjects With Advanced or Metastatic Solid Tumors

Mesothelin-targeting antibody-drug conjugate

Phase 1b Multi-indication Study of Anetumab Ravtansine (BAY 94-9343) in Patients with Mesothelin Expressing Advanced or Recurrent Malignancies

DARWIN 1

Deciphering Afatinib Response and Resistance With INtratumour Heterogeneity

Contact ECMT enquiries

DARWIN 2

Deciphering Antitumour Response and Resistance With INtratumour Heterogeneity (DARWIN II) - A phase II, multi-centre, non-randomised, molecularly stratified trial for NSCLC patients to study tumour heterogeneity using genomic analysis

Contact ECMT enquiries

HuMax®-AXL-ADC

First-in-human, open-label, dose-escalation trial with expansion cohorts to evaluate safety of Axl-specific antibody-drug conjugate (HuMax®-AXL-ADC) in patients with solid tumors

anti-PD-L1 / TGFβ-Trap molecule

A Phase 1, open label, multiple ascending dose trial to investigate the safety, tolerability, pharmacokinetcs, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumours and expansion to selected indications

Anti-PDL-1

An Open-Label, Randomised, Multi-Drug, Biomarker-Directed, Multi-Centre, Multi-arm Phase 1b Study in patients with Muscle Invasive Bladder Cancer (MIBC) who have progressed on prior treatment (BISCAY)

oral HSP90 inhibitor

A Phase I Study Evaluating TAS-116 in Patients With Advanced Solid Tumors

alpha folate receptor targeted TS inhibitor

A Phase I trial of ONX-0801 (a novel α-folate receptor-mediated thymidylate synthase inhibitor) exploring once weekly and alternate week dosing regimens in patients with solid tumours

ATM kinase inhibitor

Study to Assess the Safety and Preliminary Efficacy of AZD0156 at Increasing Doses Alone or in Combination With Other Anti-cancer Treatment in Patients With Advanced Cancer (AToM)

PTEN-deficient/Mutated or PIK3CB Mutated Advanced Solid Malignancies

A Phase I, Open-label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumour Activity of Ascending Doses of AZD8186 in Patients With Advanced Castration-resistant Prostate Cancer (CRPC), Squamous Non-Small Cell Lung Cancer (sqNSCLC), Triple Negative Breast Cancer (TNBC) and Patients With Known PTEN-deficient/Mutated or PIK3CB Mutated Advanced Solid Malignancies, With Expansion to Assess the Pharmacodynamic Activity of AZD8186

Non-CTIMP

Tumour Characterisation to Guide Experimental Targeted Therapy

Contact ECMT enquiries

ATR / PI3K inhibitor (AZD6738) in combination with Cytotoxic Chemotherapy and/or DNA Damage Repair/Novel Anti-cancer Agents

A Modular Phase I, Open-Label, Multicentre Study
to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumour Activity of AZD6738 in Combination With Cytotoxic Chemotherapy and/or DNA Damage Repair/Novel Anti-cancer Agents in Patients With Advanced Solid Malignancies

TAS3681

A Phase 1, Open-Label, Non-Randomized, Safety, Tolerability, and Pharmacokinetic Study of TAS3681 in Patients with Metastatic Castration Resistant Prostate Cancer

PEN221

A Phase 1/2a, open-label multicenter study to assess the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of PEN-221 in patients with advanced gastroenteropancreatic or lung neuroendocrine tumors or advanced small-cell lung cancer or other advanced cancers expressing somatostatin receptor 2

PDR2102

A phase Ib, multi-center, open-label study of PDR001 in combination with LCL161, panobinostat or everolimus in patients with advanced/metastatic CRC, TNBC or NSCLC

WEE-1 inhibitor

A Randomised, Open-label, Phase I Study to Determine the Effect of Formulation and Food on the Pharmacokinetics of AZD1775 After Oral Dosing of a Capsule Formulation in Patients with Advanced Solid Tumours

RXC004 (PORCN inhibitor)

A Modular, Multi-Arm, Multi-Part, Phase I/IIa, Adaptive Design Study To Evaluate The Safety And Tolerability Of RXC004, Alone And In Combination With Anti-Cancer Treatments, In Patients With Advanced Malignancies

Contact ECMT enquiries

TRIBE

TRIBE; Tyrosine Kinase Inhibitor (TKI) therapy in Renal Cell Carcinoma: Immune Biomarker Evaluation

Contact ECMT enquiries

PROACT

PROACT: Patient Reported Opinions About Clinical Tolerability.
Empowering patients participating in early clinical studies and providing a way for them to directly contribute to drug development on their own terms.

Contact ECMT enquiries

SRA737 (CHK1 inhibitor)

A phase 1 trial of SRA737 (a chk1 inhibitor) administered orally in subjects with advanced cancer.

E7386 (Wnt/ β catenin inhibitor)

An Open-Label Multicenter Phase 1 study of E7386 in Subjects with Selected Advanced Neoplasms

BGB324 (AXL inhibitor)

Phase II study of BGB324 in combination with Pembrolizumab in patients with previously treated advanced adenocarcinoma of the lung

CX-072 (PD-L1)

An open label, dose finding and proof of concept study of the PD-L1 probodyTM therapeutic, C-072, as monotherapy and in combination with Yervoy (Ipilimumab) or with Zelboraf (Vemurafenib) in subjects with advanced or recurrent solid tumours or lymphomas.

JNJ-63723283 (Anti-PDL-1)

A first-in-human, open-label, 2-part, phase I/II study to evaluate the safety, pharmacokinetics, pharmacodynamics, and clinical activity of JNJ-63723283, an anti-PD-1 antibody, in subjects with advanced cancers

GEN 701 (HuMax-TF-ADC)

First-in-human, dose-escalating safety study of tissue specific antibody drug conjugate (HuMax-TF-ADC) in patients with locally advanced and/or metastatic solid tumours known to express tissue factor.

STARTRK-2 (NTRK1/2/3, ROS1, or ALK Gene Rearrangements)

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

CT7001 (CDK7 inhibitor)

A Modular Phase I, Open-Label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumour Activity of Ascending Doses of CT7001 alone or in combination with Cytotoxic Chemotherapy and/or DNA Damage Repair/Novel Anti-cancer Agents in Patients with Solid Malignancies

OMO-1 (MET inhibitor)

A modular, multi-arm, multi-part, first time in patient study to evaluate the safety and tolerability of OMO-1, alone and in combination with anti-cancer treatments, in patients with locally advanced, unresectable or metastatic solid malignancies

AZD4785 (antisense oligonucleotide (ASO))

A Phase I, Open-Label, Multicentre Dose-Escalation Study to Investigate the Safety and Pharmacokinetics of AZD4785 in Patients with Advanced Solid Tumours Where KRAS May Be an Important Driver of Tumour Survival

PEACE Trial

The PEACE (Posthumous tissuE donAtion in CancEr) Study

Contact ECMT enquiries

MT1-MMP
(BT1718)

A Cancer Research UK Phase I/IIa clinical trial of BT1718, (bicycle peptide drug conjugate), administered intravenously as a monotherapy in patients with advanced solid tumours.

 

RAS-RAF-MEK
(FRAME)

FRAME: A Phase I trial of the combination of VS-6063 (FAK inhibitor) and RO5126766 (CH5126766) (a duel RAF/MEK inhibitor) in patients with advanced solid tumours

 Contact ECMT enquiries

MX39795 (CUPISCO study)

A phase II, randomized, active-controlled, multi-center study comparing the efficacy and safety of targeted therapy or cancer immunotherapy guided by genomic profiling versus platinum-based chemotherapy in patients with cancer of unknown primary site who have received three cycles of platinum doublet chemotherapy

 

SRA737-02

A Phase 1 Trial of SRA737 (a Chk1 Inhibitor) Administered Orally in Subjects with Advanced Cancer’ and ‘A Phase 1 trial of oral SRA737 (a Chk1 inhibitor) given in combination with gemcitabine plus cisplatin or gemcitabine alone in subjects with advanced cancer’

ATR Inhibitor (VX970) in combination with cytotoxic chemo

An Open-Label, First-in-Human Study of the Safety, Tolerability, and Pharmacokinetics of VX-970 in Combination with Either Gemcitabine or Cisplatin and Etoposide in Subjects with Advanced Solid Tumors